<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>573</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15336780</PubmedId>
            <Abstract>A role of CD4(+) cells in the regulation of immune responses has steadily gained renewed recognition. The understanding of these T-regulatory (T-reg) cells in the generation of antitumor cytolytic T lymphocyte (CTL) response is therefore important. It has been shown that immunization with specific peptides, DNA, or tumor lysate-based vaccines can induce CTL responses in vivo. We have immunized melanoma patients with major histocompatibility complex (MHC) class I restricted peptide- or melanoma tumor lysate-loaded antigen-presenting cell (APC)-based vaccines and have monitored the generation of CTL responses and T-reg cell responses, if any. Using tetramer staining and limiting dilution analyses as monitors of CTL responses, we found significant increases in the number of antigen-specific CTL in circulation after vaccination with the MART-1(27-35) peptide (AAGIGILTV)-pulsed autologous APC, the MAGE-1(161-169) peptide (EADPTGHSY)-pulsed APC, or with autologous tumor lysate-pulsed APC. The antigen-specific CTL reached the peak expansion by day 7 and then declined to the prevaccine levels by day 28. The decline in the CTL response was associated by a concomitant expansion of CD4(+) CD25(+)T cells. Analysis of postvaccine peripheral blood lymphocytes (PBL) from patients showed an increased amount of interleukin (IL)-10 secretion on in vitro stimulation with IL-2 after successive vaccination. Triple color flow cytometric analyses revealed cytoplasmic IL-10 in the CD4(+)CD25(+) T-cell fraction and the number of CD4(+)CD25(+) IL-10(+) T cells were found to increase significantly in postvaccine PBL. These observations have implications in tumor antigen and APC/dendritic cell (DC)-based cancer vaccine strategies.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>794-802</ArticlePages>
            <ArticleTitle>Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Chakraborty</LastName>
                    <ForeName>Nitya G</ForeName>
                </Author>
                <Author>
                    <LastName>Chattopadhyay</LastName>
                    <ForeName>Subhasis</ForeName>
                </Author>
                <Author>
                    <LastName>Mehrotra</LastName>
                    <ForeName>Shikhar</ForeName>
                </Author>
                <Author>
                    <LastName>Chhabra</LastName>
                    <ForeName>Arvind</ForeName>
                </Author>
                <Author>
                    <LastName>Mukherji</LastName>
                    <ForeName>Bijay</ForeName>
                </Author>
            </Authors>
            <Affiliations>Division of Hematology/Oncology, Department of Medicine, University of Connecticut Health Center, Farmington, CT., USA. chakraborty@uchc.edu</Affiliations>
            <ArticleChemicalList>Antigens, Neoplasm;Cancer Vaccines;HLA-A Antigens;HLA-A*02:01 antigen;HLA-A2 Antigen;Isoantigens;MAGEA1 protein, human;MART-1 antigen (27-35), Leu(28)-beta-HIle(30)-;Melanoma-Specific Antigens;Neoplasm Proteins;Peptide Fragments;Peptides;Interleukin-10</ArticleChemicalList>
            <ArticleMeshHeadingsList>Antigen-Presenting Cells(immunology); Antigens, Neoplasm; CD4-Positive T-Lymphocytes(immunology); Cancer Vaccines(immunology); HLA-A Antigens(chemistry; immunology); HLA-A2 Antigen; Humans; Interleukin-10(analysis; immunology); Isoantigens(immunology); Lymphocytes, Tumor-Infiltrating(drug effects; immunology); Melanoma(drug therapy; immunology); Melanoma-Specific Antigens; Neoplasm Proteins(immunology); Peptide Fragments(immunology); Peptides(immunology); T-Lymphocytes, Cytotoxic(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>65</Volume>
                <Issue>8</Issue>
                <Title>Human immunology</Title>
                <Issn>0198-8859</Issn>
                <MedlineTa>Hum Immunol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>MART-1&lt;sub&gt;27-35&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>AAGIGILTV</LinearSequence>
                        <StartingPosition>27</StartingPosition>
                        <EndingPosition>35</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>Q16655.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 794</LocationOfData>
                <EpitopeId>155</EpitopeId>
                <ReferenceStartingPosition>27</ReferenceStartingPosition>
                <ReferenceEndingPosition>35</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1A</LocationOfData>
                        <TCellId>4958</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>235</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Other</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AAGIGILTV</LinearSequence>
                                            <StartingPosition>27</StartingPosition>
                                            <EndingPosition>35</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MART-1&lt;sub&gt;27-35&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intradermal</Route>
                                <DoseSchedule>Four intradermal injections with 1 x 10&lt;sup&gt;7&lt;/sup&gt; autologous myeloid APC (grown in granulocyte macrophage colony stimulating factor [GM-CSF]) pulsed with synthetic peptide.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>AAGIGILTV</LinearSequence>
                                            <StartingPosition>27</StartingPosition>
                                            <EndingPosition>35</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>Q16655.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with metastatic melanoma and patients with no active disease but who were considered at high risk of recurrence where enroled for peptide vaccination.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MART-1&lt;sub&gt;27-35&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>AAGIGILTV</LinearSequence>
                                        <StartingPosition>27</StartingPosition>
                                        <EndingPosition>35</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>Q16655.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>7</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>The tetramer assay showed significant increases in the numberof tetramer-positive cells by day 7 post vaccination. However, the number of epitope-specific CTL declined to the baseline levels by day 28 post vaccination.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>MAGE-1&lt;sub&gt;161-169&lt;/sub&gt;</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EADPTGHSY</LinearSequence>
                        <StartingPosition>161</StartingPosition>
                        <EndingPosition>169</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P43355.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 794</LocationOfData>
                <EpitopeId>11010</EpitopeId>
                <ReferenceStartingPosition>161</ReferenceStartingPosition>
                <ReferenceEndingPosition>169</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <TCellId>4961</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>233</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Other</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EADPTGHSY</LinearSequence>
                                            <StartingPosition>161</StartingPosition>
                                            <EndingPosition>169</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P43355.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>MAGE-1&lt;sub&gt;161-169&lt;/sub&gt;</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intradermal</Route>
                                <DoseSchedule>Four intradermal injections with 1 x 10&lt;sup&gt;7&lt;/sup&gt; autologous myeloid APC (grown in granulocyte macrophage colony stimulating factor [GM-CSF]) pulsed with synthetic peptide.</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EADPTGHSY</LinearSequence>
                                            <StartingPosition>161</StartingPosition>
                                            <EndingPosition>169</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P43355.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with metastatic melanoma and patients with no active disease but who were considered at high risk of recurrence where enroled for peptide vaccination.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>233</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>MAGE-1&lt;sub&gt;161-169&lt;/sub&gt;</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EADPTGHSY</LinearSequence>
                                        <StartingPosition>161</StartingPosition>
                                        <EndingPosition>169</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P43355.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The positive response was seen 7 days post vaccination in two patients.  IL-2 (50 units/ml) was included in the assay culture medium.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

